ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas
نویسندگان
چکیده
منابع مشابه
ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
BACKGROUND Platinum resistance constitutes one of the most recognized clinical challenges for ovarian cancer. Notably, the detection of the primary tumor-based excision repair cross-complementation group 1 (ERCC1) protein by immunohistochemistry was recently shown to be inaccurate for the prediction of platinum resistance. On the basis of the previous finding that circulating tumor cells (CTC) ...
متن کاملERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.
This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinum-based chemotherapy in patients with late-stage bladder cancer. A total of 41 eligible patients histologically confirmed as having stage IV muscle-invasive transitional cell carcinoma of the bladder were treated with platinum-based chemotherapy for 2-6 cycles. The genotypes of ...
متن کاملStudy of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
This study was designed to evaluate the effect of excision repair crosscomplementing group 1 (ERCC1) rs11615 codon 118C/T gene polymorphisms ontreatment outcomes in Iranian patients receiving oxaliplatin-based regimens forcolorectal (CRC) and gastric cancers (GC). Patients, who were candidates to receiveoxaliplatin-based chemotherapy, entered into the study. In 2-week in...
متن کاملStudy of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
This study was designed to evaluate the effect of excision repair crosscomplementing group 1 (ERCC1) rs11615 codon 118C/T gene polymorphisms ontreatment outcomes in Iranian patients receiving oxaliplatin-based regimens forcolorectal (CRC) and gastric cancers (GC). Patients, who were candidates to receiveoxaliplatin-based chemotherapy, entered into the study. In 2-week in...
متن کاملERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
Background: Possible targeted therapies for metastatic triple negative breast cancer (TNBC) include cytotoxic chemotherapy that causes interstrand breaks (platinum-based drugs). The excision repair cross-complementation 1 (ERCC1) enzyme plays an essential role in the nucleotide excision repair pathway, removing platinum-induced DNA adducts and contributing to cisplatin resistance. Detecting ERC...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Endocrinology
سال: 2018
ISSN: 0804-4643,1479-683X
DOI: 10.1530/eje-17-0788